Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 20/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13668472 | 0.86 | CNR1 (1.00) | CNR1KCNH2CYP3A4CYP2C8CYP2D6 | |
| SCHEMBL4388145 | 0.84 | CNR1 (0.76) | CNR1KCNH2CYP3A4CYP2C8CYP2D6 | |
| SCHEMBL13668473 | 0.83 | CNR1 (0.74) | CNR1KCNH2CYP3A4CYP2C8CYP2D6 | |
| SCHEMBL4393958 | 0.83 | CNR1 (0.79) | CNR1KCNH2CYP3A4CYP2C8CYP2D6 | |
| SCHEMBL4390248 | 0.81 | CNR1 (0.70) | CNR1KCNH2CYP3A4CYP2C8CYP2D6 | |
| SCHEMBL4275583 | 0.80 | CNR1 (0.80) | CNR1KCNH2CYP3A4CYP2C8CYP2D6 | |
| SCHEMBL14297903 | 0.80 | CNR1 (0.80) | CNR1KCNH2 | |
| SCHEMBL10080912 | 0.80 | CNR1 (1.00) | CNR1KCNH2 | |
| SCHEMBL4394591 | 0.78 | CNR1 (0.76) | CNR1KCNH2CYP3A4CYP2C8CYP2D6 | |
| SCHEMBL4388162 | 0.77 | CNR1 (1.00) | CNR1KCNH2CYP3A4CYP2C8CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247499-A1 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2009-10-01 | — | — | US | claimed |
| EP-2056828-A2 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2009-05-13 | — | — | EP | claimed |
| WO-2008024284-A2 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-02-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247499-A1 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | CNR1, CNR2, FAAH | CNR1 1/4885KCNH2 1914/4885CYP3A4 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.